Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy.
作者信息
Petersen Ronald C
机构信息
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
出版信息
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S88-90. doi: 10.1016/j.jalz.2007.11.004. Epub 2007 Dec 21.
Abstract
摘要
相似文献
1
Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy.
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S88-90. doi: 10.1016/j.jalz.2007.11.004. Epub 2007 Dec 21.
2
Leon Thal's vision for the treatment and prevention of Alzheimer's disease.
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S150-2. doi: 10.1016/j.jalz.2007.12.002.
3
Current and future management of Alzheimer's disease.
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S48-50. doi: 10.1016/j.jalz.2007.11.010. Epub 2007 Dec 21.
4
Dementia: is it time for a change in focus?
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S77-84. doi: 10.1016/j.jalz.2007.09.004. Epub 2007 Dec 21.
5
Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention.
CNS Drugs. 2019 Feb;33(2):99-106. doi: 10.1007/s40263-018-0598-1.
6
Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
J Alzheimers Dis. 2016;50(4):927-45. doi: 10.3233/JAD-150826.
7
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges.
Alzheimers Dement. 2009 Mar;5(2):166-71. doi: 10.1016/j.jalz.2008.12.002.
8
Perspective: in search of biomarkers.
Nature. 2011 Jul 13;475(7355):S8. doi: 10.1038/475S8a.
9
Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment.
J Nutr Health Aging. 2010 Apr;14(4):304-5. doi: 10.1007/s12603-010-0068-z.
10
Alzheimer's drugs take a new tack.
Nature. 2012 Sep 6;489(7414):13-4. doi: 10.1038/489013a.
本文引用的文献
1
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
Neurology. 2007 Oct 16;69(16):1622-34. doi: 10.1212/01.wnl.0000295996.54210.69.
2
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
Nat Med. 2007 Nov;13(11):1359-62. doi: 10.1038/nm1653. Epub 2007 Oct 14.
3
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Lancet Neurol. 2007 Jun;6(6):501-12. doi: 10.1016/S1474-4422(07)70109-6.
4
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Arch Neurol. 2007 Mar;64(3):354-62. doi: 10.1001/archneur.64.3.354.
5
Mild cognitive impairment should be considered for DSM-V.
J Geriatr Psychiatry Neurol. 2006 Sep;19(3):147-54. doi: 10.1177/0891988706291085.
6
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.
Arch Neurol. 2006 May;63(5):674-81. doi: 10.1001/archneur.63.5.674.
7
Neuropathologic features of amnestic mild cognitive impairment.
Arch Neurol. 2006 May;63(5):665-72. doi: 10.1001/archneur.63.5.665.
8
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Lancet Neurol. 2006 Mar;5(3):228-34. doi: 10.1016/S1474-4422(06)70355-6.
9
Neuropathologic substrate of mild cognitive impairment.
Arch Neurol. 2006 Jan;63(1):38-46. doi: 10.1001/archneur.63.1.38.
10
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
J Nucl Med. 2005 Oct;46(10):1625-32.
Zotero 插件